

10031181

08/07/2003

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADDEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN

Kamal Saeed

10031181

08/07/2003

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 42 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 43 Jun 06 PASCAL enhanced with additional data
NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:42:36 ON 08 JUL 2003

=> FILE REG		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:42:44 ON 08 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUL 2003 HIGHEST RN 544408-69-7
DICTIONARY FILE UPDATES: 7 JUL 2003 HIGHEST RN 544408-69-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 10031181.str

Kamal Saeed

10031181


08/07/2003

L1 STRUCTURE UPLOADED

=> D

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1 FULL

FULL SEARCH INITIATED 09:43:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 62 TO ITERATE

100.0% PROCESSED 62 ITERATIONS

50 ANSWERS

SEARCH TIME: 00.00.01

L2 50 SEA SSS FUL L1

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 09:43:17 ON 08 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

Kamal Saeed

10031181

08/07/2003

FILE COVERS 1907 - 8 Jul 2003 VOL 139 ISS 2
FILE LAST UPDATED: 7 Jul 2003 (20030707/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> S L2

L3 4 L2

=> D IBIB ABS HI5TSTR TOT

'HI5TSTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

Kamal Saeed

10031181

08/07/2003

KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END


=> D IBIB ABS HITSTR TOT

10031181

08/07/2003


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:675381 CAPLUS
DOCUMENT NUMBER: 137:348354
TITLE: Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor
AUTHOR(S): Feng, Yiqing; Likos, John J.; Zhu, Leiming; Woodward, Harold; Munie, Grace; McDonald, Joseph J.; Stevens, Anna M.; Howard, Carol P.; De Crescenzo, Gary A.; Welsch, Dean; Shieh, Huey-Sheng; Stallings, William
C. CORPORATE SOURCE: Discovery Research, Pharmacia Corporation, St. Louis, MO, 63017, USA
SOURCE: Biochimica et Biophysica Acta (2002), 1598 (1-2), 10-23
CODEN: BBACAQ; ISSN: 0006-3002
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB MMP-2 is a member of the matrix metalloproteinase family that has been implicated in tumor cell metastasis and angiogenesis. Here, we describe the soln. structure of a catalytic domain of MMP-2 complexed with a hydroxamic acid inhibitor (SC-74020), detd. by three-dimensional heteronuclear NMR spectroscopy. The catalytic domain, designated MMP-2C, has a short peptide linker replacing the internal fibronectin-domain insertion and is enzymically active. Distance geometry-simulated annealing calcs. yielded 14 converged structures with a root-mean-square deviations (r.m.s.d.) of 1.02 and 1.62 Å, from the mean coordinate positions for the backbone and for all heavy atoms, resp., when 11 residues at the N-terminus are excluded. The structure has the same global fold as obsd. for other MMP catalytic domains and is similar to previously solved crystal structures of MMP-2. Differences obsd. between the soln. and the crystal structures, near the bottom of the S 1' specificity loop, appear to be induced by the large inhibitor present in the soln. structure. The MMP-2C soln. structure is compared with MMP-8 crystal structure bound to the same inhibitor to highlight the differences esp. in the S 1' specificity loop. The finding provides a structural explanation for the selectivity between MMP-2 and MMP-8 that is achieved by large inhibitors.
IT 321596-00-3DP, SC 74020, complexes with matrix metalloproteinase-2
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(soln. structure and backbone dynamics of catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor)
RN 321596-00-3 CAPLUS
CN Benzamide, N-[4-[[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-pentyl- (9CI) (CA INDEX NAME)
Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:63016 CAPLUS
DOCUMENT NUMBER: 134:136687
TITLE: Method of changing conformation of a matrix metalloproteinase
INVENTOR(S): Stallings, William C.; Shieh, Huey S.; Howard, Susan C.; De Crescenzo, Gary A.; McDonald, Joseph J.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2001005389 A2 20010125 WO 2000-US16323 20000712
WO 2001005389 A3 20010802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MG, SD, SL, SE, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 2002003994 A1 20020117 WO 2000-US21024 20000801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MG, SD, SL, SE, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1999-144133 P 19990716
WO 2000-US16323 W 20000712
OTHER SOURCE(S): MARPAT 134:136687
GI



AB The present invention provides a matrix metalloproteinase inhibiting
Kamal Saeed

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)
compd. having structure or a salt, an enantiomer, a diastereomer, a racemate, or a tautomer thereof. The present invention provides a method of changing the conformation of a matrix metalloproteinase, a method of inhibiting a matrix metalloproteinase, and a method of treating osteoarthritis. An example was given for the prepn. of I and another example given for cloning, expression and purifn. of the catalytic domain of MMP-8.
IT 213204-15-0P 213204-16-1P 213204-69-4P
321596-00-3P 321596-01-4P 321596-03-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(changing conformation of a matrix metalloproteinase and enzyme inhibitors)
RN 213204-15-0 CAPLUS
CN Benzamide, N-[4-[[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-pentyl-, monohydrochloride (9CI) (CA INDEX NAME)
Absolute stereochemistry.




● HCl

RN 213204-16-1 CAPLUS
CN Benzamide, 4-hexyl-N-[4-[[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)
Absolute stereochemistry.

10031181

08/07/2003


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl

RN 213204-69-4 CAPLUS
 CN D-Valine, N-[2-(4-morpholinyl)ethyl]-N-[[4-[(4-pentylbenzoyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 321596-00-3 CAPLUS
 CN Benzamide, N-[4-[[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

IT 213204-68-3P 213204-70-7P 213204-71-8P
 213204-72-9P 213204-73-0P
 RL: RCT (Reactant); SPW (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (changing conformation of a matrix metalloproteinase and enzyme
 inhibitors)

RN 213204-68-3 CAPLUS
 CN D-Valine, N-[2-(4-morpholinyl)ethyl]-N-[[4-[(4-pentylbenzoyl)amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213204-70-7 CAPLUS
 CN Benzamide, N-[4-[[[(1R)-2-methyl-1-[[[tetrahydro-2H-pyran-2-yl]oxy]amino]carbonyl]propyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Kamal Saeed

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 321596-01-4 CAPLUS
 CN Benzamide, 4-hexyl-N-[4-[[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 321596-03-6 CAPLUS
 CN D-Valine, N-[2-(4-morpholinyl)ethyl]-N-[[4-[(4-pentylbenzoyl)amino]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-71-8 CAPLUS
 CN D-Valine, N-[4-[(4-hexylbenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213204-72-9 CAPLUS
 CN D-Valine, N-[4-[(4-hexylbenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10031181

08/07/2003

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)
monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 213204-15-0 CAPLUS
CN Benzamide, N-[4-[[[1R]-1-[(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-pentyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 213204-16-1 CAPLUS
CN Benzamide, 4-hexyl-N-[4-[[[1R]-1-[(hydroxyamino)carbonyl]-2-

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 213204-18-3 CAPLUS
CN Benzamide, 4-bromo-N-[4-[[[1R]-1-[(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 213204-19-4 CAPLUS

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzenepropanamide, N-hydroxy-, alpha-[[[2-(4-morpholinyl)ethyl][4-[[4-pentylbenzoyl]amino]phenyl]sulfonyl]amino]-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 213204-20-7 CAPLUS
CN Benzamide, N-[4-[[[1R]-2-(hydroxyamino)-1-methyl-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 213204-22-9P 213204-23-0P 213204-24-1P
213204-25-2P 213204-45-6P 213204-47-8P
213204-49-0P 213204-51-4P 213204-53-6P
213204-55-8P 213204-63-8P 213204-64-9P
213204-65-0P 213204-66-1P 213204-67-2P
213204-68-3P 213204-69-4P 213204-70-7P
213204-71-8P 213204-72-9P 213204-73-0P
213204-80-9P 213204-81-0P 213204-82-1P
213204-83-2P 213204-87-6P 213204-88-7P
213204-89-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of amidoarom. ring sulfonamide hydroxamic acids)

Kamal Saeed


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 213204-22-9 CAPLUS
CN D-Valine, N-[4-[[4-butylbenzoyl]amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213204-23-0 CAPLUS
CN D-Valine, N-[4-[[4-(benzoylamino)phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213204-24-1 CAPLUS
CN D-Valine, N-[4-[[4-(benzoylamino)phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10031181

08/07/2003


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl

RN 213204-25-2 CAPLUS
 CN Benzamide, N-[4-[[[(1R)-2-methyl-1-[[[tetrahydro-2H-pyran-2-yl]oxy]amino]carbonyl]propyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213204-45-6 CAPLUS
 CN D-Alanine, N-[[4-[[[(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 213204-53-6 CAPLUS
 CN D-Alanine, N-[[4-[[[(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213204-55-8 CAPLUS
 CN D-Alanine, N-[[4-[[[(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213204-63-8 CAPLUS
 CN D-Valine, N-[2-(4-morpholinyl)ethyl]-N-[[4-[[[(4-propylbenzoyl)amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Kamal Saeed

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 213204-47-8 CAPLUS
 CN D-Alanine, N-[[4-[[[(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213204-49-0 CAPLUS
 CN D-Alanine, N-[[4-[[[(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213204-51-4 CAPLUS
 CN D-Alanine, N-[[4-[[[(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-64-9 CAPLUS
 CN D-Valine, N-[2-(4-morpholinyl)ethyl]-N-[[4-[[[(4-propylbenzoyl)amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213204-65-0 CAPLUS
 CN Benzamide, N-[4-[[[(1R)-2-methyl-1-[[[tetrahydro-2H-pyran-2-yl]oxy]amino]carbonyl]propyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10031181


08/07/2003

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-66-1 CAPLUS
 CN D-Valine, N-[[4-[(4-butylbenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213204-67-2 CAPLUS
 CN Benzamide, 4-butyl-N-[4-[[[(1R)-2-methyl-1-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]propyl][2-(4-morpholinylethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-68-3 CAPLUS
 CN D-Valine, N-[2-(4-morpholinylethyl)-N-[[4-[(4-pentylbenzoyl)amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213204-69-4 CAPLUS
 CN D-Valine, N-[2-(4-morpholinylethyl)-N-[[4-[(4-pentylbenzoyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-70-7 CAPLUS
 CN Benzamide, N-[4-[[[(1R)-2-methyl-1-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]propyl][2-(4-morpholinylethyl)amino]sulfonyl]phenyl]-4-pentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213204-71-8 CAPLUS
 CN D-Valine, N-[[4-[(4-hexylbenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-72-9 CAPLUS
 CN D-Valine, N-[[4-[(4-hexylbenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213204-73-0 CAPLUS
 CN Benzamide, 4-hexyl-N-[4-[[[(1R)-2-methyl-1-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]propyl][2-(4-morpholinylethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10031181


08/07/2003

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-80-9 CAPLUS
 CN D-Valine, N-[[4-(benzoylamino)phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213204-81-0 CAPLUS
 CN D-Valine, N-[[4-(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 213204-87-6 CAPLUS
 CN D-Phenylalanine, N-[2-(4-morpholinyl)ethyl]-N-[[4-(4-pentylbenzoyl)amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213204-88-7 CAPLUS
 CN D-Phenylalanine, N-[2-(4-morpholinyl)ethyl]-N-[[4-(4-pentylbenzoyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 213204-82-1 CAPLUS
 CN D-Valine, N-[[4-(4-bromobenzoyl)amino]phenyl]sulfonyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213204-83-2 CAPLUS
 CN Benzamide, 4-bromo-N-[4-[[[(1R)-2-methyl-1-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]propyl]]2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 213204-89-8 CAPLUS
 CN Benzenepropanamide, .alpha.-[[2-(4-morpholinyl)ethyl][[4-(4-pentylbenzoyl)amino]phenyl]sulfonyl]amino]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


Kamal Saeed

10031181


08/07/2003

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:87604 CAPLUS
 DOCUMENT NUMBER: 128:167263
 TITLE: Preparation of N-(mercaptoethyl) (benzene or alkyl)sulfonamide derivatives or their disulfides as metalloprotease inhibitors
 INVENTOR(S): Decrescenzo, Gary; Abbas, Zaheer S.; Freskos, John N.; Getman, Daniel P.; Heintz, Robert M.; Mischke, Brent V.; et al.
 PATENT ASSIGNEE(S): Monsanto Co., USA; Decrescenzo, Gary; Abbas, Zaheer S.; Freskos, John N.; Getman, Daniel P.
 SOURCE: PCT Int. Appl., 301 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803166	A1	19980129	WO 1997-US12873	19970722
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CM, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SE, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9738903	A1	19980210	AU 1997-38903	19970722
AU 740263	B2	20011101		
BR 9710752	A	19990817	BR 1997-10752	19970722
EP 939629	A1	19990908	EP 1997-936168	19970722
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,			
FI	CN	1238688	A	19991215
		NZ	333825	A
		JP	20000515153	T2
		NZ	506464	A
		RU	2202540	C2
		NO	9900247	A
PRIORITY APPLN. INFO.:		US	1996-22040P	P
		NZ	1997-333825	A1
		NO	1997-US12873	W
OTHER SOURCE(S):		MARPAT	128:167263	
GI				




L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 202750-88-7 CAPLUS
 CN Benzamide, N-[4-[[[2-amino-1-(mercaptomethyl)-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 202750-89-8 CAPLUS
 CN Benzamide, N-[4-[[[2-amino-1-(mercaptomethyl)-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-chloro-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202750-90-1 CAPLUS
 CN Benzamide, N-[4-[[[2-amino-1-(mercaptomethyl)-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-chloro-, monohydrochloride,

Kamal Saeed

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)

AB This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfonamide inhibitors for matrix metalloproteinase (MMP-13), compns. of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the prepn. of proteinase inhibitors and processes for treating pathol. conditions assocd. with pathol. matrix metalloproteinase activity related to MMP-13. The title compds. are represented by formula HSCH2CH(R2)SO2R1, R9C(=W)SCH2CH(R4)N(R2)SO2R1, or R1SO2N(R2)CH(R4)CH2S-CH2CH(R4)N(R2)SO2R1 [R1 = a radical having a length greater than that of a satd. four carbon chain and shorter than that of a satd. eighteen carbon chain, and when rotated about an axis drawn through the SO2-bonded 1-position and the 4-position of a 6-membered ring or the SO2-bonded position and substituent-bonded 3- or 5-membered ring defines a three-dimensional vol. whose widest dimension has the width of about one Ph ring to about three Ph rings in a direction to that axis to rotation; R2 = H, C1-6 alkyl, alkyl substituted by amino or mono- or disubstituted amino; R4 = CO2H, CONH2, C1-6 alkyl; W = O, S; R9 = C1-6 alkyl, C1-6 alkoxy, single-ringed carbocyclic or heterocaryl; provided that R2 = H only when R1 = 4-(phenylazo)phenyl]. They are useful for the treatment of the diseases in which known and new MMP enzymes are implicated, e.g. uncontrolled breakdown of connective tissue by metalloproteinases leading to rheumatoid

arthritis, osteoarthritis, tumor metastasis, etc. Thus, N-[(R)-2-hydroxy-1-methylethyl]-N-methyl-4-methoxybenzenesulfonamide (prepn. given) underwent Mitsunobu reaction with thioacetic acid using Ph3P and di-Et azodicarboxylate in THF at 0.degree. for 0.5 h followed by treatment with NaOMe in MeOH to give N-[(R)-2-mercapto-1-methylethyl]-N-methyl-4-methoxybenzenesulfonamide (I; R = OMe, R2 = Me, R4 = Me). The latter compd. and I (R = SPh, R2 = G, R4 = CONH2) in vitro showed IC50 of 300 and 2,060 nM, resp., against MMP-1 and 32.5 and <0.1 nM, resp., against MMP-13.

IT 202750-87-6P 202750-88-7P 202750-89-8P

202750-90-1P 202750-91-2P 202750-92-3P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-(mercaptoethyl) (benzene or alkyl)sulfonamide derivs. or their disulfides as metalloprotease inhibitors and therapeutics)

RN 202750-87-6 CAPLUS


CN Benzamide, N-[4-[[[2-amino-1-(mercaptomethyl)-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)

(R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 202750-91-2 CAPLUS

CN Benzamide, N-[4-[[[2-amino-1-(mercaptomethyl)-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-bromo-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202750-92-3 CAPLUS


CN Benzamide, N-[4-[[[2-amino-1-(mercaptomethyl)-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-bromo-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10031181

08/07/2003


L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)



● HCl

IT 202752-08-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of N-(mercaptoethyl)(benzene or alkyl)sulfonamide derivs. or
 their disulfides as metalloprotease inhibitors and therapeutics)
 RN 202752-08-7 CAPLUS
 CN Benzamide,
 N-[4-[[[2-amino-2-oxo-1-[[[triphenylmethyl]thio]methyl]ethyl] [2-
 (4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-, (R)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

10031181

08/07/2003

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.65

169.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.60

-2.60

STN INTERNATIONAL LOGOFF AT 09:46:44 ON 08 JUL 2003

Kamal Saeed